Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/f1a4e2ab-f5aa-4e2a-a584-fe2de4dd522d/

SYNCOMF

Syncom Formulations (India) Limited
Chart
₹14.49
Latest Week 2026-06-05
HealthcareDrug Manufacturers - Specialty & GenericLARGE
Snapshot 2026-06-07 · 0.0w · Fresh
0.24
OS Score
37.0%
Value
71.0%
Quality
12.0%
Momentum
6/9
F-Score
0.513
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
2 of 23 passing
★
OS Composite
✗
↗
Trending Value
✗
◆
Quality × Value
✗
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
✗
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
✗
📈
Consistent Earners
Noneyr
🌱
GARP
Rev +76%
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
37.0%ile
P/E
19.8×
P/S
2.8×
P/B
3.6×
E/P
0.0506
FCF Yield
0.010
EBITDA/EV
0.071
SH Yield
0.000
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
69.00000000
/100 — 1=cheapest
VC2 (Trending Value)
69.00000000
/100
VC3 (Buyback)
70.00000000
/100
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
71.0%ile
ROE
0.182
ROA
0.151
Net Margin
0.139
Op Margin
0.148
GPA
0.407
Current
4.68
F-Score
6/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.764
Earn Growth
0.953
Stability
0.136
lower=better
Accruals
0.100
lower=better
5yr Consist
Yes
Accruals ratio of 0.100 is elevated — earnings quality may be lower than headline numbers suggest.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
12.0%ile
6M Return
-4.3%
12M Return
-30.1%
12-1 Mom
-29.3%
Risk-Adj
-0.79
Vol 252d
37.0%
Vol 60d
87.7%
↑ Expanding
Max DD 12M
-49.1%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
12-1 momentum of -29% signals a downtrend — price is moving against you. Near-term vol (88%) is expanding vs long-term (37%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.24
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 160 peers
Sector Value %ile
64.0%
Sector Quality %ile
54.0%
P/E z-score
-0.23
P/B z-score
-0.40
Sector Avg OS
43.8%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
NATCOPHARM NATCO Pharma Limited 98.0% 88.0% 87.0% 81.0%
UNIVPHOTO Universus Photo Imagings Limited 97.0% 86.0% 74.0% 94.0%
LINCOLN Lincoln Pharmaceuticals Limited 97.0% 88.0% 80.0% 81.0%
STAR Strides Pharma Science Limited 96.0% 73.0% 91.0% 91.0%
VENUSREM Venus Remedies Limited 96.0% 68.0% 94.0% 99.0%
HALEOSLABS Haleos Labs Limited 95.0% 82.0% 77.0% 81.0%
AUROPHARMA Aurobindo Pharma Limited 94.0% 71.0% 84.0% 87.0%
SPARC Sun Pharma Advanced Research Company Limited 93.0% 72.0% 86.0% 83.0%
Factor Interactions
Growth at Reasonable Price
Revenue growing 76% with P/E of 20×. Growth isn't fully priced in.
Earnings Quality Concern
ROE looks strong (18%) but high accruals (0.100) suggests earnings are accrual-heavy, not cash-backed.
Volatility Expanding
60-day vol (88%) significantly exceeds 252-day (37%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
D
44.4% avg (7 factors)
Quality
B
64.1% avg (7 factors)
Momentum
F
9.3% avg (4 factors)
Risk
C
54.9% avg (1 factors)
High quality business commanding a premium price. The market recognises the quality — returns from here depend on continued fundamental execution. Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Factor Persistence1 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.240—1—
Value %ile0.370—0—
Quality %ile0.710—1—
Momentum %ile0.120—1—
F-Score6.000—0—
Confidence0.839—1—
Volatility0.370—0—
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
19.75
Earnings Yield (E/P)
0.0506
Price / Sales
2.75
Price / Book
3.60
Price / Cash Flow
58.12
FCF Yield
1.0%
EBITDA / EV
7.1%
Sales Yield (1/P·S)
0.3633
Shareholder Yield
Div + net buyback / mktcap
0.0%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
18.2%
Return on Assets
15.1%
Net Margin
13.9%
Operating Margin
14.8%
Gross Profit / Assets
Novy-Marx GPA
40.7%
Current Ratio
4.68
Accruals Ratio
(NI-OCF)/Assets — lower=better
0.100
MomentumPrice trend strength over different horizons
6M Return
-4.3%
12M Return
-30.1%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
-29.3%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
-0.79
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
76.4%
Earnings Growth (YoY)
95.3%
Earnings Stability (CV)
Lower = more stable
0.136
5yr Consistent
EPS up every year for 5 years
Yes
Piotroski F-Score
6
Dividend Yield
0.0%
Buyback Yield
0.0%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
69
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
69
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
70
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity